There are 2137 resources available
LBA37 - A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Presenter: Java Walladbegi
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
890MO - Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Presenter: Eleni Tholouli
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA20 - Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Presenter: Robert Jones
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1022MO - Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Presenter: Anders Kverneland
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1027MO - ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)
Presenter: Ulka Vaishampayan
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA42 - POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy
Presenter: Sheela Rao
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1023MO - AMC 095: A report of nivolumab (nivo) in advanced HIV associated solid tumours (ST)
Presenter: Lakshmi Rajdev
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1024MO - A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer
Presenter: Petri Bono
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1025MO - First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
Presenter: Ignacio Melero
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1026MO - Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours
Presenter: Daniel Karp
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast